Title: (Es)Ketamine and other RAADs in the treatment of depression - hype or hope?
Speaker: Andreas Reif, Germany
Outline: In this talk Dr Andreas Reif will explore the paradigm shift in depression treatment with intranasal esketamine, the first NMDA antagonist antidepressant, offering a novel mechanism of action compared to traditional antidepressants. Dr Reif will examine the unique properties of esketamine, its safety profile, and other emerging drugs targeting the NMDA receptor, such as dextromethorphan/bupropion. The presentation concludes outlining the challenges and ongoing trials of NMDA-based treatments, highlighting the potential of glutamate system targeting for faster, more effective antidepressants in the future.
PsychX webinar series: Mental health expertise should be readily available to all. PsychX conducts monthly sessions, fostering short and interactive discussions focused on translational neuroscience. This webinar series is organised by the ECNP PsychX Programme Committee.
This online series provides valuable insights for researchers and clinicians while promoting networking opportunities within the professional community.
